Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › IMPACT

IMPACT

Pemvidutide · MASH F2–F3

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Pemvidutide
Population
MASH F2–F3
Official title
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Sponsor
Altimmune, Inc.
Phase
Phase 2
Registry status
completed · 2023-07 → 2025-11
Participants
212
Duration
24 weeks
Registry
NCT05989711

Outcomes in the indication

IMPACT Pemvidutide · MASH F2–F3 · 24 weeks · n = 212 abstract

MASH resolution without worsening of fibrosis +38 / +32 percentage points vs placebo at 24 weeks (1.2 / 1.8 mg); fibrosis improvement +5 / +8, not significant. At 48 weeks (no biopsy): liver fat −37.1 / −46.5 percentage points vs placebo.

MeasureDrugControlDifference (95 % CI)Status
MASH resolution without worsening of fibrosis 1.2 mg
week 24
+58.0+20.0+38.0 (+21.0 to +56.0) percentage pointsabstract
MASH resolution without worsening of fibrosis 1.8 mg
week 24
+52.0+20.0+32.0 (+19.0 to +46.0) percentage pointsabstract
Fibrosis improvement (≥1 stage) without worsening of MASH 1.2 mg
week 24
+33.0+28.0+5.0 (−13.0 to +22.0) percentage pointsabstract
Fibrosis improvement (≥1 stage) without worsening of MASH 1.8 mg
week 24
+36.0+28.0+8.0 (−6.0 to +22.0) percentage pointsabstract
Verbatim quotes (4)
  • MASH resolution without worsening of fibrosis
    MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1.2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0.0001), and 45 (52%) of 85 patients in the 1.8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0.0001)
  • MASH resolution without worsening of fibrosis
    MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1.2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0.0001), and 45 (52%) of 85 patients in the 1.8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0.0001)
  • Fibrosis improvement (≥1 stage) without worsening of MASH
    Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1.2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0.59), and 30 (36%) of 85 patients in the 1.8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0.27)
  • Fibrosis improvement (≥1 stage) without worsening of MASH
    Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1.2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0.59), and 30 (36%) of 85 patients in the 1.8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0.27)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: IMPACT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/impact/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.